Aygestin Shortage: What Providers and Prescribers Need to Know in 2026

For providers prescribing Norethindrone Acetate (formerly marketed as Aygestin), 2026 has brought continued questions from patients about medication access. This briefing provides an evidence-based overview of current availability, supply chain factors, prescribing considerations, and practical resources to support your patients.

Provider Briefing: Current Status

Norethindrone Acetate 5 mg oral tablets remain FDA-approved and actively manufactured by multiple generic producers. The original brand-name Aygestin has been discontinued, but generic availability continues.

Key points for your practice:

• No official FDA or ASHP shortage listing for oral Norethindrone Acetate as of early 2026
• Patients are experiencing intermittent "spot shortages" at retail pharmacies, particularly large chains
• The estradiol/norethindrone acetate transdermal patch (CombiPatch) has experienced separate documented shortages — this is a distinct product
• Broader hormone supply chain disruptions continue to create secondary demand pressures

Timeline: How We Got Here

Understanding the context helps frame current prescribing decisions:

• Brand discontinuation: Teva discontinued brand-name Aygestin, consolidating all supply among generic manufacturers
• 2023–2024: Widespread hormone therapy supply disruptions affected estradiol, progesterone, and combination products across the U.S. and UK
• 2024–2025: CombiPatch (estradiol/norethindrone acetate transdermal system) entered documented shortage, creating confusion among patients who conflate this with oral Norethindrone Acetate
• 2025–2026: Limited generic manufacturer base for oral Norethindrone Acetate 5 mg results in inconsistent retail availability, though national supply remains adequate

Prescribing Implications

The intermittent availability of Norethindrone Acetate has several implications for clinical practice:

Prescription Routing

Consider sending prescriptions electronically to pharmacies that are more likely to stock the medication. Independent pharmacies and specialty pharmacies often have better access through multiple wholesaler relationships. Mail-order pharmacy may also be appropriate for stable patients on maintenance therapy.

Dosing Considerations

Norethindrone Acetate is available only as a 5 mg oral tablet. Standard dosing by indication:

• Secondary amenorrhea: 2.5 to 10 mg daily for 5 to 10 days during the second half of the menstrual cycle
• Abnormal uterine bleeding: 2.5 to 10 mg daily for 5 to 10 days, starting on day 16 or 21 of the cycle
• Endometriosis: 5 mg daily for 2 weeks, increasing by 2.5 mg every 2 weeks up to 15 mg daily; maintained 6 to 9 months

Important: Norethindrone Acetate 5 mg is not interchangeable with norethindrone 0.35 mg (progestin-only contraceptive mini-pill). These are distinct products with different potencies and indications.

Patient Communication

Proactively addressing availability with patients can reduce anxiety and prevent treatment gaps:

• Inform patients that generic Norethindrone Acetate is still manufactured and available — the challenge is pharmacy-level stocking, not national supply
• Encourage patients to request refills 7 to 10 days before running out
• Provide patients with the names of pharmacies likely to stock the medication, or direct them to Medfinder for Providers as a stock-checking resource

Availability Picture: Where to Find It

Current availability patterns for Norethindrone Acetate 5 mg:

• Independent pharmacies: Generally the most reliable source. Multiple wholesaler relationships provide ordering flexibility.
• Chain pharmacies: Inconsistent stocking. Automated ordering systems may not prioritize lower-volume medications. However, most chains can special-order within 1 to 3 business days.
• Mail-order pharmacies: Good option for stable patients. Larger inventory capacity typically means better availability.
• Specialty/compounding pharmacies: Can prepare custom formulations if manufactured tablets are temporarily unavailable in a region.

Medfinder for Providers offers real-time pharmacy stock data that can be shared with patients or used by clinical staff to identify in-stock pharmacies before prescribing.

Cost and Access Considerations

Cost should not be overlooked as a barrier to access:

• Retail cash price: $50 to $115 for 30 tablets (generic Norethindrone Acetate 5 mg)
• With discount coupons: $10 to $15 for 30 tablets through GoodRx, SingleCare, or similar programs
• Insurance coverage: Generally covered on Tier 1 or Tier 2 formularies; prior authorization is uncommon for FDA-approved indications
• Patient assistance: Teva Cares Foundation (877-237-4881, tevacares.org) may provide eligible Teva generics at no cost. NeedyMeds and RxAssist maintain directories of additional programs.

For uninsured or underinsured patients, advising them to use a discount coupon can reduce their out-of-pocket cost by 70% to 80% compared to retail pricing. See our patient-facing guide: How to save money on Aygestin.

Tools and Resources for Your Practice

• Medfinder for Providers: Real-time pharmacy stock search. Help patients find in-stock pharmacies before they leave your office.
• FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages — check for official shortage listings
• ASHP Drug Shortage Resource Center: ashp.org/drug-shortages — clinical guidance and alternative recommendations
• Discount coupon programs: GoodRx, SingleCare, RxSaver — recommend to patients paying cash

Therapeutic Alternatives

When Norethindrone Acetate is genuinely unavailable, evidence-based alternatives include:

• Medroxyprogesterone Acetate (Provera): 2.5 to 10 mg oral daily. Most direct substitute for amenorrhea and abnormal uterine bleeding. Widely available; generic costs approximately $4 to $15 per month.
• Levonorgestrel IUD (Mirena): Continuous local progestin delivery. FDA-approved for heavy menstrual bleeding. Effective for endometriosis-related symptoms in appropriate candidates.
• Elagolix (Orilissa): GnRH antagonist, FDA-approved for moderate to severe endometriosis pain. Different mechanism from progestins. Higher cost ($900+ per month) and bone density concerns with extended use.
• Megestrol Acetate (Megace): Oral progestin. Less commonly used as an Aygestin substitute but may be appropriate for select patients with endometrial hyperplasia.

For detailed patient-facing information on alternatives, refer patients to: Alternatives to Aygestin.

Looking Ahead

The supply picture for generic Norethindrone Acetate is expected to remain stable but not abundant in 2026. Key factors to watch:

• Any new generic manufacturers entering the market (would increase supply resilience)
• Resolution of broader hormone supply chain disruptions
• Potential new progestin formulations or delivery systems in the pipeline

Staying informed about supply trends helps you anticipate patient needs and adjust prescribing strategies proactively.

Final Thoughts

Norethindrone Acetate remains a valuable and effective therapeutic option for endometriosis, amenorrhea, and abnormal uterine bleeding. The current availability challenges are primarily distribution-level rather than supply-level. By routing prescriptions strategically, utilizing real-time stock-checking tools like Medfinder for Providers, and preparing patients with alternatives and cost-saving resources, you can help ensure continuity of care.

For additional provider resources, see our companion guide: How to help your patients find Aygestin in stock.